The FDA has allowed the use of GE Healthcare's SPECT imaging agent AdreView, also known as iobenguane I-123, in the evaluation of myocardial sympathetic innervation in patients with New York Heart Association class II or III heart failure and left-ventricular ejection fraction at or lower than 35%. The company said the agent has the potential to detect the likelihood that patients' heart failure will advance.
FDA OKs additional indication for SPECT agent AdreView
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan